{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T02:11:12Z","timestamp":1755828672793,"version":"3.44.0"},"reference-count":20,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"5","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: To analyse the effects of statins on the levels of sCD40, sCD146 and PAPP-An in patients with coronary heart disease (CHD). Methods: 126 patients with CHD treated from September 2022 to September 2024 were divided into a study group (n = 84) and a control group (n=42). The study group was randomly divided into groups A (n=42) and B (n=42). Patients in the control group were routinely treated with vasodilator, furosemide, digitalis and other cardiotonic agents. Based on routine treatment, patients in the study group were treated with Atto vastatin calcium tablets in group An and rosuvastatin calcium tablets in group B. Both groups were treated with 20 mg, oral administration before bedtime, and the treatment cycle was 3 months. The cardiac function grade, blood lipid level, serum sCD40, sCD146 and PAPP-A levels and adverse reactions were compared before and after treatment. Results: After treatment, the cardiac function of the three groups improved compared with that before treatment. The effect of patients in groups A and B was better than the control group. The blood lipid levels of the three groups were improved after treatment. The blood lipid levels of groups A and B were better than in the control group. The serum sCD40, sCD146, and PAPP-A levels between groups A and B were no different; after treatment, these in groups A and B were better than those in the control group. After treatment, there were some adverse reactions in all the three groups. Conclusions: Statins effectively treat sCD40, sCD146, and PAPP-An in patients with CHD. They can significantly improve their cardiac function and blood lipid levels and effectively regulate sCD40, sCD146, and PAPP-An levels in patients with coronary heart disease<\/jats:p>","DOI":"10.5937\/jomb0-55833","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:01:51Z","timestamp":1742533311000},"page":"1003-1008","source":"Crossref","is-referenced-by-count":0,"title":["Effects of statins on serum sCD40, sCD146 and PAPP-An in patients with coronary heart disease"],"prefix":"10.5937","volume":"44","author":[{"given":"Huawen","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Danesh J, Whincup P Walker M, Lennon L, Thomson A, Appleby P , et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321(7255): 199-204;","DOI":"10.1136\/bmj.321.7255.199"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Xue X, Liu Y, Yang M, Wang S, Huang M, Gao S, et al. Effect of hypercholesterolemia alone or combined with hypertension on the degree of coronary artery stenosis in patients with coronary heart disease angina pectoris: A medical records based retrospective study protocol. Medicine (Baltimore) 2020; 99(38): e22225-e;","DOI":"10.1097\/MD.0000000000022225"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Joynt Maddox KE, Elkind MSV, Aparicio HJ, Commodore-Mensah Y, de Ferranti SD, Dowd WN, et al. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050-Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. Circulation 2024; 150(4): e65-e88;","DOI":"10.1161\/CIR.0000000000001256"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Jia G, Sowers JR. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension 2021; 78(5): 1197-205;","DOI":"10.1161\/HYPERTENSIONAHA.121.17981"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Caterina RD RF, Marzilli M. What dictates prognosis in myocardial ischemic syndromes: myocardial ischemia or coronary atherosclerosis? Heart and Metabolism 2020(81): 23-6;","DOI":"10.31887\/HM.2020.81\/rdecaterina"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Parikh RR, Folsom AR, Misialek JR, Rosamond WD, Chang PP, Tang W , et al. Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure. Thromb Res 2019; 182: 89-94;","DOI":"10.1016\/j.thromres.2019.08.009"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, Rorth R, Jackson A, et al. Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol 2022; 21(1): 110;","DOI":"10.1186\/s12933-022-01545-1"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Sayols-Baixeras S, Llufs-Ganella C, Lucas G, Elosua R. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet 2014; 7: 15-32;","DOI":"10.2147\/TACG.S35301"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Alonso R, Perez de Isla L, Muniz-Grijalvo O, Diaz-Diaz JL, Mata P . Familial Hypercholesterolaemia Diagnosis and Management. Eur Cardiol 2018; 13(1): 14-20;","DOI":"10.15420\/ecr.2018:10:2"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Chen L, Chen X-W, Huang X, Song B-L, Wang Y Wang Y. Regulation of glucose and lipid metabolism in health and disease. Science China Life Sciences 2019; 62(11): 1420-58;","DOI":"10.1007\/s11427-019-1563-3"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"de Padua Borges R, Degobi NAH, Bertoluci MC. Choosing statins: a review to guide clinical practice. Arch Endocrinol Metab 2021; 64(6): 639-53;","DOI":"10.20945\/2359-3997000000306"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P Troupis T The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. Curr Cardiol Rev 2017; 13(3): 209-16;","DOI":"10.2174\/1573403X13666170426104611"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Lopau K, Wanner C. Treatment rationale for coronary heart disease in advanced CKD. Herz 2021; 46(3): 221-7;","DOI":"10.1007\/s00059-021-05025-2"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bedi U, Singh M, Singh P Molnar J, Khosla S, Arora R. Effects of statins on progression of coronary artery disease as measured by intravascular ultrasound. J Clin Hypertens (Greenwich) 2011; 13(7): 492-6;","DOI":"10.1111\/j.1751-7176.2011.00428.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, et al. Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals 2022; 15(2): 151;","DOI":"10.3390\/ph15020151"},{"key":"ref16","unstructured":"Yang S-W, Zhou Y-J, Zhao Y-X, Liu YY, Tian X-F, Wang Z-J, et al. The serum anion gap is associated with disease severity and all-cause mortality in coronary artery disease. Journal of Geriatric Cardiology: JGC 2017; 14(6): 392;"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zhang X, Kang J, Zhang J, Chen Y, Dai H, Hu M, et al. Effectiveness of Yiqi Fumai lyophilised injection for acute heart failure: Rationale and design of the AUGUST-AHF cohort study. Front Cardiovasc Med 2023; 9: 1074406;","DOI":"10.3389\/fcvm.2022.1074406"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Huang S-H, Wu C-H, Jiang S, Bahner I, Lossinsky Albert S, Jong Ambrose Y HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities. Biochemical Journal 2011; 438(3): 457-66;","DOI":"10.1042\/BJ20110218"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Shami A, Edsfeldt A, Bengtsson E, Nilsson J, Shore AC, Natali A, et al. Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype. J Stroke 2021; 23(3): 367-76;","DOI":"10.5853\/jos.2021.00178"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Chinetti G, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Current Opinion in Lipidology 2003; 14(5): 459-68;","DOI":"10.1097\/00041433-200310000-00006"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Efekti statina na nivoe serumskih sCD40, sCD146 i PAPP-An kod pacijenata sa koronarnom bole\u0161\u0107u srca"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582505003L.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T13:54:21Z","timestamp":1755784461000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582505003L"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-55833","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"type":"print","value":"1452-8258"},{"type":"electronic","value":"1452-8266"}],"subject":[],"published":{"date-parts":[[2025]]}}}